Abstract 430P
Background
Teenagers and young adults (age 15-29) are increasingly the focus of cancer care in India. Young persons from rural western Madhya Pradesh, a resource crunch area, need provided support, and a care pathway to ensure optimal results in the treatment of cancer.
Methods
Disease characteristics of TYA patients over (30 months) from 2018-thru 2020 were analyzed. Abandonment defined as. Failure to start / complete treatment was quantified, and the cancers were documented by the Birch classification. Early deaths (within 30 days) and trends to completion of therapy were documented. Telephonic tracing of patients, escorting them to hospital, providing accommodation, food caregiver support. Since Feb 2019, the state sponsored Insurance scheme Ayushman Bharat provided TYAs access to cancer care.
Results
Two hundred and forty six cancer patients’ records in the age group 15-29 years were. analysed in a retrospective study. Median age 23 years; M: F 166: 80. Diseases were classified by the Birch Classification: Leukemias 84; Lymphomas. 45; Brain 6; Bone tumors 55; Soft tissue tumors 6; Germ Cell tumors 19; Carcinoma 30; Miscellaneous 1; Twenty two (9%) abandoned treatment. 65 (26%) alive after completed therapy; Early deaths occurred in 56 (23%); as of 30 June 2020, 103 (41%) are alive on treatment.
Conclusions
Early deaths occurred on account of poor nutrition; delayed diagnosis; toxicity of therapy.TYAcan Foundation provided diagnostic, treatment and accommodation support; mitigating early morbidity and mortality; tracking young persons to reduce abandonment. Early trends indicate that the government Ayushman Scheme and the social entrepreneurship of TYAcan together helped establish a viable care pathway for young cancer patients to achieve to survival rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Medical Oncology, Sri Aurobindo Institute of Medical sciences.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
51P - Real world outcomes in elderly women with HER2-positive advanced breast cancer
Presenter: Nicole Evans
Session: e-Poster Display Session
52P - Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study)
Presenter: Yookija Kang
Session: e-Poster Display Session
53P - Aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor treated HR+/HER2- metastatic breast cancer differ to those treated with Aromatase inhibitors alone on progression
Presenter: Indunil Weerasena
Session: e-Poster Display Session
54P - Platinum-based chemotherapy in advanced breast cancer (ABC): Real-world outcome from a tertiary cancer centre in India
Presenter: Indhuja Vijesh
Session: e-Poster Display Session
55P - Eribulin in heavily pretreated metastatic breast cancer: A real-world data from India
Presenter: Tanmoy Mandal
Session: e-Poster Display Session
56P - Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study
Presenter: Yiqi Yang
Session: e-Poster Display Session
57P - Therapeutic vulnerability of malignant phyllodes tumour to pazopanib identified through a novel patient-derived xenograft and cell line model
Presenter: Dave Ng
Session: e-Poster Display Session
58P - Survival benefit of local treatments in breast cancer with lung metastasis: Results from a large retrospective study
Presenter: Yimeng Chen
Session: e-Poster Display Session
59P - The impact of site of metastasis on overall survival in indigenous and non-indigenous patients of Western Australia with breast cancer
Presenter: Azim Khan
Session: e-Poster Display Session
60P - Risk factors of bone metastasis and skeletal-related events in high-risk breast cancer patients
Presenter: Sumadi Lukman Anwar
Session: e-Poster Display Session